Title:
CRYSTAL FORM OF TAFAMIDIS FREE ACID, PREPARATION METHOD THEREFOR AND USE THEREOF
Document Type and Number:
WIPO Patent Application WO/2021/232619
Kind Code:
A1
Abstract:
A crystal form of tafamidis free acid (I) and a preparation method therefor, a pharmaceutical composition comprising the crystal form, and use of the crystal form in the preparation of a medicament for treating diseases caused by transthyretin amyloidosis. The crystal form of tafamidis free acid has one or more improved properties with respect to the prior art, having significant value for the optimization and development of the medicament in the future.
More Like This:
| JP2015522546 | Inhibitors of activity of mitochondrial electron transport chain complex (III) and their use |
| WO/2021/105261 | TRPM8 MODULATORS |
| JP2024513943 | Bicyclic heteroaromatic inhibitors of KLK5 |
Inventors:
CHEN MINHUA (CN)
ZOU SIMING (CN)
ZOU SIMING (CN)
Application Number:
PCT/CN2020/113444
Publication Date:
November 25, 2021
Filing Date:
September 04, 2020
Export Citation:
Assignee:
CRYSTAL PHARMACEUTICAL SUZHOU CO LTD (CN)
International Classes:
A61K31/423; C07D263/57; A61P9/00; A61P25/00
Domestic Patent References:
| WO2020232325A1 | 2020-11-19 | |||
| WO2019175263A1 | 2019-09-19 |
Foreign References:
| CN106715405A | 2017-05-24 | |||
| CN103781770A | 2014-05-07 | |||
| CN107344927A | 2017-11-14 |
Other References:
ANONYMOUS: "VYNDAQEL (tafamidis meglumine) PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION", PFIZER CANADA ULC, 20 January 2020 (2020-01-20), XP055873610, Retrieved from the Internet
Download PDF: